Duma Discusses the Unique Challenges of Women With Lung Cancer
In Partnership With:
Dr Duma discusses the leading causes of lung cancer in women, the ongoing failure to screen a sufficient number of women for lung cancer, and how gender bias interferes with treatment.
Welcome to OncLive On Air®! I’m your host today, Jason Harris.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, the first of a two-part series, I spoke with Narjust Duma, MD, an assistant professor of medicine at Harvard Medical School, and physician and associate director of the Cancer Equity Program at Dana-Farber Cancer Institute, about lung cancer in women.
Lung cancer is far and away the leading cause of cancer deaths in American women, accounting for nearly 20,000 more deaths in 2022 than the number 2 cause, breast cancer. Moreover, the American Lung Association says that although lung cancer incidence has dropped by 36% in men since the mid 1970s, incidence in women has increased by 84% in that time.
In our exclusive interview, Dr Duma discussed the leading causes of lung cancer in women, the ongoing failure to screen a sufficient number of women for lung cancer, and how gender bias interferes with treatment.
___
That’s all we have for today! Thanks again to my guest, Dr Narjust Duma, and to you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field, and join me again on July 4th for part 2 of my conversation with Dr Duma.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
